Familial hypertrophic cardiomyopathy
MONDO:0024573Hypertrophic cardiomyopathy caused by mutations in the genes encoding components of the sarcomere, in the absence of predisposing conditions.
Also known as: cardiomyopathy, familial hypertrophic, familial hypertrophic cardiomyopathy, familila or idiopathic hypertrophic obstructive cardiomyopathy, hereditary hypertrophic cardiomyopathy, hypertrophic familial cardiomyopathy
94 clinical trials for this condition and its sub-types, 2 tagged with Familial hypertrophic cardiomyopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial hypertrophic cardiomyopathy
-
Myotonic dystrophy type 1 45 trials
1 sub-type
-
Noonan syndrome and Noonan-related syndrome 1 trial · 29 incl. sub-types
6 sub-types
- Noonan syndrome 22 trials · 25 incl. sub-types Sub-types →
- Costello syndrome 7 trials
- Cardiofaciocutaneous syndrome 7 trials Sub-types →
- Legius syndrome 5 trials
- Noonan syndrome with multiple lentigines 3 trials Sub-types →
- Noonan syndrome-like disorder with loose anagen hair 0 trials Sub-types →
-
Beckwith-Wiedemann syndrome 6 trials
8 sub-types
- Beckwith-Wiedemann syndrome due to 11p15 microdeletion 0 trials
- Beckwith-Wiedemann syndrome due to 11p15 microduplication 0 trials
- Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion 0 trials
- Beckwith-Wiedemann syndrome due to CDKN1C mutation 0 trials
- Beckwith-Wiedemann syndrome due to NSD1 mutation 0 trials
- Beckwith-Wiedemann syndrome due to imprinting defect of 11p15 0 trials
- Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11 0 trials
- Franceschini Vardeu Guala syndrome 0 trials
-
Dilated cardiomyopathy 1C 1 trial
-
5 sub-types
- Glutaric acidemia IIa 0 trials
- Glutaric acidemia IIb 0 trials
- Glutaric acidemia IIc 0 trials
- Multiple acyl-CoA dehydrogenase deficiency, mild type 0 trials
- Multiple acyl-CoA dehydrogenase deficiency, severe neonatal type 0 trials
-
46,XY complete gonadal dysgenesis 0 trials · 1 incl. sub-types
12 sub-types
- 46,XY sex reversal 5 1 trial
- 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency 0 trials
- 46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome 0 trials
- 46,XY sex reversal 1 0 trials
- 46,XY sex reversal 10 0 trials
- 46,XY sex reversal 11 0 trials
- 46,XY sex reversal 2 0 trials
- 46,XY sex reversal 3 0 trials
- 46,XY sex reversal 4 0 trials
- 46,XY sex reversal 6 0 trials
- 46,XY sex reversal 7 0 trials
- 46,XY sex reversal 9 0 trials
-
Dilated cardiomyopathy 1KK 0 trials
-
Hypertrophic cardiomyopathy 1 0 trials
-
Hypertrophic cardiomyopathy 10 0 trials
-
Hypertrophic cardiomyopathy 11 0 trials
-
Hypertrophic cardiomyopathy 12 0 trials
-
Hypertrophic cardiomyopathy 13 0 trials
-
Hypertrophic cardiomyopathy 14 0 trials
-
Hypertrophic cardiomyopathy 15 0 trials
-
Hypertrophic cardiomyopathy 16 0 trials
-
Hypertrophic cardiomyopathy 17 0 trials
-
Hypertrophic cardiomyopathy 18 0 trials
-
Hypertrophic cardiomyopathy 19 0 trials
-
Hypertrophic cardiomyopathy 2 0 trials
-
Hypertrophic cardiomyopathy 20 0 trials
-
Hypertrophic cardiomyopathy 21 0 trials
-
Hypertrophic cardiomyopathy 25 0 trials
-
Hypertrophic cardiomyopathy 26 0 trials
-
Hypertrophic cardiomyopathy 3 0 trials
-
Hypertrophic cardiomyopathy 4 0 trials
-
Hypertrophic cardiomyopathy 6 0 trials
-
Hypertrophic cardiomyopathy 7 0 trials
-
Hypertrophic cardiomyopathy 8 0 trials
-
Hypertrophic cardiomyopathy 9 0 trials
Most studied deeper sub-types
-
New hope for muscle disease: experimental drug VX-670 enters human trials
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called VX-670 in 52 adults with myotonic dystrophy type 1 (DM1), a genetic condition that causes muscle weakness and other problems. Participants receive either VX-670 or a placebo, and researchers will monito…
Phase 1/2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New hope for DM1: Long-Term trial of AOC 1001 underway
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of an experimental drug called AOC 1001 (del-desiran) for people with myotonic dystrophy type 1 (DM1), a genetic muscle disorder. The trial enrolls 230 adults who have completed a prior AOC 1001 study and will r…
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Weekly shot may help short kids grow – new study underway
Disease control OngoingThis study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Vertex tests long-term safety of VX-670 for muscle disease
Disease control By invitation onlyThis study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…
Phase 2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a short course of steroids calm a dangerous heart rhythm?
Disease control By invitation onlyThis trial tests whether an 8-week course of the immunosuppressive drug prednisone can reduce episodes of ventricular tachycardia (a potentially fatal fast heart rhythm) and improve heart function in people with non-ischemic cardiomyopathy and confirmed heart inflammation. Partic…
Phase 4 • Sponsor: Roderick Tung • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Weekly shot could replace daily needles for kids with growth disorders
Disease control OngoingThis study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New pill may replace chemo for kids with brain tumors
Disease control OngoingThis study tests a new drug called DAY101 (tovorafenib) against standard chemotherapy for children and young adults with a type of brain tumor called low-grade glioma that has a specific gene change (RAF alteration). The goal is to see if the new drug works better at shrinking tu…
Phase 3 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to help kids with rare genetic short stature grow taller
Disease control OngoingThis study tests a drug called vosoritide in 56 children with short stature caused by certain genetic conditions. The drug targets the growth plate to help children grow faster. Participants are observed for 6 months, then treated with daily injections for 12 months to check safe…
Phase 2 • Sponsor: Andrew Dauber • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Super MRI could spot hidden heart damage
Diagnosis OngoingThis study tests whether a new, more powerful 7 Tesla MRI can better detect scarring and swelling in the heart muscle of people with cardiomyopathy. Researchers will scan 13 adults aged 20-70 to see if the higher-resolution images improve diagnosis. The goal is to see if this adv…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Music therapy tested for rare muscle disease in kids
Symptom relief OngoingThis study explores whether weekly music and movement sessions are practical and enjoyable for children aged 6 to 18 with myotonic dystrophy type 1 (DM1). Over 10 weeks, participants attend 45-minute music classes, undergo physical and cognitive tests, and provide biological samp…
Sponsor: Hanns Lochmuller • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief By invitation onlyThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Hope for myotonic dystrophy: new drug shows promise in easing muscle stiffness Long-Term
Symptom relief By invitation onlyThis study is testing the long-term safety and effectiveness of a drug called mexiletine PR for people with myotonic dystrophy types 1 and 2. The drug is taken once daily as a liquid to help reduce muscle stiffness (myotonia). The study includes 176 adults and teens who have alre…
Phase 3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can a gene registry unlock the secrets of childhood heart failure?
Knowledge-focused OngoingThis study gathers health information from children under 18 who have cardiomyopathy linked to mutations in the MYBPC3 gene. Researchers aim to map the disease's natural course, identify risk factors, and measure how it affects quality of life. By reviewing past and future medica…
Sponsor: Tenaya Therapeutics • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Brain scans aim to unlock mysteries of muscle disease
Knowledge-focused By invitation onlyThis study looks at how myotonic dystrophy types 1 and 2 affect the brain. About 100 adults aged 30-65 will have MRI scans, thinking and movement tests, and blood draws. Some will also have a spinal tap. The goal is to find brain changes that could be used as markers in future tr…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New study tracks how DM1 affects chinese patients over time
Knowledge-focused By invitation onlyThis study follows 1000 Chinese patients with myotonic dystrophy type 1 (DM1) to understand how the disease affects multiple body systems and leads to disability. Researchers will collect health data and blood samples every 3 to 6 months for several years. The goal is to identify…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Brain scans reveal diabetes link to cognitive decline in rare disease
Knowledge-focused OngoingThis study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study aims to uncover why people with muscle disease fall
Knowledge-focused OngoingThis study measures how often people with myotonic dystrophy type 1 fall and what factors affect their balance. Researchers will also assess fear of falling and leg muscle strength. The goal is to better understand fall risk in this condition.
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New digital tool aims to tame uncontrolled asthma in GP practices
Knowledge-focused OngoingThis study tests a digital tool called AsthmaOptimiser that helps doctors assess asthma control and find ways to improve treatment during a single visit. About 746 adults with asthma who have had recent flare-ups will take part. The goal is to see if the tool can identify better …
Sponsor: General Practitioners Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New registry to monitor growth hormone treatment in kids with rare condition
Knowledge-focused By invitation onlyThis study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on growth, side effects, and quality of life over time. No new treatment is being tested—the g…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC